MedTrace Logo

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

NCT02549573 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-09-01

Study results available
· View outcomes & findings →

Summary

To determine if PT intervention will be improved while in the "on" motor state vs. the "end-of-dose-off" motor state during the PT Intervention Visit in subjects with PD.

Conditions

Interventions

DRUG

APOKYN

Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.

BEHAVIORAL

Physical Therapy

All subjects will participate in a standardized PT intervention

Sponsors & Collaborators

  • MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Mark Pirner, MD · US WorldMeds

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549573 on ClinicalTrials.gov